![]() Abrocitinib, 100 mg daily, baricitinib, 4 mg and 2 mg daily, and tralokinumab, 300 mg, every 2 weeks were associated with slightly worse scores.Ĭonflict of Interest Disclosures: The authors declare no potential conflicts of interest involving the work under consideration for publication. In this systematic review and meta-analysis, abrocitinib, 200 mg and upadacitinib, 30 mg daily, were associated with slightly better scores than dupilumab, and upadacitinib, 15 mg daily, was associated with similar scores to dupilumab. The pattern of results was similar for POEM, DLQI, and PP-NRS. ![]() There was little or no difference between upadacitinib, 15 mg daily, and dupilumab (MD, 0.2 95% CrI, -1.9 to 2.2 high certainty). Abrocitinib, 100 mg daily (MD, -2.1 95% CrI, -4.1 to -0.3 high certainty), baricitinib, 4 mg daily (MD, -3.2 95% CrI, -5.7 to -0.8 high certainty), baricitinib, 2 mg daily (MD, -5.2 95% CrI, -7.5 to -2.9 high certainty) and tralokinumab, 600 mg then 300 mg every 2 weeks (MD, -3.5 95% CrI, -5.8 to -1.3 high certainty) were associated with reduced EASI slightly less than dupilumab. Up to 16 weeks of treatment in adults, abrocitinib, 200 mg daily (mean difference, 2.2 95% credible interval, 0.2-4.0 high certainty) and upadacitinib, 30 mg daily (MD, 2.7 95% CrI, 0.6-4.7 high certainty) were associated with reduced EASI slightly more than dupilumab, 600 mg then 300 mg every 2 weeks. Since October 2019, 21 new studies were added, for a total of 60 trials with 16 579 patients. Outcomes include change in Eczema Area and Severity Index (EASI), Patient Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), and Peak Pruritus Numeric Rating Scales (PP-NRS). The updated analysis was completed from June to December 2021. Bayesian network meta-analyses and assessed Grading of Recommendations Assessment, Development and Evaluation certainty of evidence were performed. ![]() Randomized clinical trials examining 8 or more weeks of treatment with systemic immunomodulatory medications for moderate-to-severe atopic dermatitis were included after screening titles, abstracts, and papers in duplicate.ĭata were abstracted in duplicate. The Cochrane Central Register of Controlled Trials, MEDLINE, Embase, Latin American and Caribbean Health Science Information database, Global Resource of EczemA Trials database, and trial registries were searched through June 15, 2021. ![]() To compare reported measures of efficacy and assessments of safety in clinical trials of systemic treatments for atopic dermatitis in a living systematic review and network meta-analysis. Systemic treatments for atopic dermatitis are being evaluated primarily in placebo-controlled trials network meta-analysis can provide relative efficacy and safety estimates for treatments that have not been compared head to head. 12 Center for Evidence-Based Healthcare, Faculty of Medicine Carl Gustav Carus, Technische Universität (TU) Dresden, Dresden, Germany.11 Department of Dermatology, Amsterdam Public Health/Infection and Immunology, Amsterdam, the Netherlands.10 Patient Representative (independent), Nottingham, United Kingodm.9 Dutch Association for People with Atopic Dermatitis (VMCE), Nijkerk, the Netherlands.8 Libraries & Collections, King's College London, London, United Kingodm.7 Departments of Medicine and Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.6 Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Manchester, United Kingodm.5 Brown University, Providence, Rhode Island.4 Unit for Population-Based Dermatology Research, St John's Institute of Dermatology, King's College London and Guy's and St Thomas' Hospital, London, United Kingdom.3 Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.2 Department of Medicine and Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.1 Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |